BNT327
Multiple Cancer Types
Phase 2/3Active
Key Facts
About BioNTech
BioNTech SE is a publicly-traded immunotherapy powerhouse founded by scientists and physicians to translate science into survival through innovative mRNA technologies. The company gained global recognition for its COVID-19 vaccine developed with Pfizer and is now applying its mRNA expertise to cancer immunotherapies and other infectious diseases. With over 25 Phase 2 and Phase 3 oncology trials and a €2.10 billion R&D investment planned for 2025, BioNTech is positioning itself as a leader in personalized cancer treatment and next-generation vaccines.
View full company profileTherapeutic Areas
Other Multiple Cancer Types Drugs
| Drug | Company | Phase |
|---|---|---|
| Keytruda (pembrolizumab) | Merck | Commercial |
| Opdivo (nivolumab) | Bristol Myers Squibb | Commercial |
| Camrelizumab (SHR-1210) | Jiangsu Hengrui Medicine | Approved |
| LENVIMA (lenvatinib) | Eisai | Commercial |